Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

Liver diseases are any diseases that affect the functioning of the liver. Liver diseases can be inherited (such as Wilson disease and alpha 1-antitrypsin deficiency) or acquired (for example ...

Weight loss drugs like Ozempic have gained a lot of popularity However these medications are not without side effects One ...

Both Wegovy and Ozempic are semaglutide – a drug that first entered the US market in 2017 as a diabetes medication. It was ...

Unlike semaglutide, ecnoglutide preferentially targets the production ... such as sleep apnoea, fatty liver disease, chronic kidney disease and heart disease, he adds. “It’ll give us options and it ...

Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

MEP Alessandra Moretti noted that non-communicable diseases (NCDs) account for 90% of EU deaths but receive just 2.8% of health budgets. She emphasised the need for enhanced screening and increased ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...